DiaMedica Therapeutics Inc. (DMAC)
Automate Your Wheel Strategy on DMAC
With Tiblio's Option Bot, you can configure your own wheel strategy including DMAC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol DMAC
- Rev/Share 0.0
- Book/Share 0.7925
- PB 4.8202
- Debt/Equity 0.0093
- CurrentRatio 8.0219
- ROIC -0.8496
- MktCap 163814970.0
- FreeCF/Share -0.5275
- PFCF -7.2485
- PE -6.0616
- Debt/Assets 0.0081
- DivYield 0
- ROE -0.6135
- Rating C+
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | DMAC | H.C. Wainwright | -- | Buy | -- | $7 | Oct. 7, 2024 |
News
DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
Published: May 19, 2025 by: Business Wire
Sentiment: Neutral
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing a novel treatment for preeclampsia, announced today that it will host a virtual key opinion leader (KOL) event on Wednesday, May 28, 2025, at 8:00 AM ET to provide further insight into the current treatment landscape of preeclampsia and the clinical trial design and endpoints of the DM199 Phase 2 preeclampsia study. The webinar will feature Prof. Stephen Ton.
Read More
DiaMedica Therapeutics Inc. (DMAC) Q1 2025 Earnings Call Transcript
Published: May 14, 2025 by: Seeking Alpha
Sentiment: Neutral
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q1 2025 Earnings Conference Call May 14, 2025 8:00 AM ET Company Participants Rick Pauls - President and Chief Executive Officer Scott Kellen - Chief Financial Officer Conference Call Participants Thomas Flaten - Lake Street Matthew Caufield - H.C. Wainwright Chase Knickerbocker - Craig-Hallum Operator Good morning ladies and gentlemen, and welcome to the DiaMedica Therapeutics First Quarter 2025 Conference Call.
Read More
DiaMedica Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Published: February 10, 2025 by: Business Wire
Sentiment: Neutral
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company's management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12th, 2025 at 11:20am Eastern Time. Investors and attendees that would like to schedule a meeting with DiaMedica's management can contact their Oppenheimer representative to a.
Read More
About DiaMedica Therapeutics Inc. (DMAC)
- IPO Date 2012-08-03
- Website https://www.diamedica.com
- Industry Biotechnology
- CEO Mr. Dietrich John Pauls MBA
- Employees 27